Skip to main content
HLB Genex, Inc. logo

HLB Genex, Inc. — Investor Relations & Filings

Ticker · 187420 ISIN · KR7187420005 KO Manufacturing
Open in API
Filings indexed 261 across all filing types
Latest filing 2026-03-30 Declaration of Voting R…
Country KR South Korea
Listing KO 187420

About HLB Genex, Inc.

http://hlbgenex.com/

HLB Genex, Inc. is a biotechnology company that develops and produces customized enzyme and microbiome-based solutions. The company's core activities involve the research, development, and manufacturing of industrial special enzymes and bio-healthcare ingredients. Its key products include enzymes like Lactase for food applications, Catalase for eco-friendly industrial processes, and Proteinase K for molecular diagnostics. In the bio-healthcare segment, it produces Vitamin K2 (Menaquinone 7) for bone and cardiovascular health and Phytosphingosine for cosmeceuticals. The company utilizes proprietary platform technologies, such as Microbial Surface Display and Spore Biologics, to develop its products and advance its pipeline of microbiome therapeutics by identifying effector molecules, also known as postbiotics.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a formal disclosure of the results of the 2026 Annual General Meeting, listing approved resolutions, vote percentages, record date, meeting date, and related details. It is not the meeting notice but the actual voting results announcement. This matches Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-30 Korean
기업설명회(IR)개최
Investor Presentation Classification · 87% confidence The document is an announcement for a corporate investor relations meeting (“기업설명회(IR) 개최”) detailing the date, time, location, participants, purpose, and distribution of IR materials. This corresponds to an Investor Presentation event rather than a financial report, earnings release, or regulatory filing. Therefore, it should be classified under the Investor Presentation category.
2026-03-25 Korean
기업설명회(IR)개최
Investor Presentation Classification · 75% confidence The document is a notice of an upcoming corporate ‘Investor Relations (IR)’ presentation event, detailing date, time, venue, agenda and distribution of IR materials. This corresponds to an Investor Presentation announcement in our taxonomy, so it should be classified under the investor presentation category (IP).
2026-03-25 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for HLB Genex Co., Ltd. (에이치엘비제넥스 주식회사) for the fiscal years 2024 and 2025. It includes the independent auditor's opinion, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows), and accompanying notes. This is a comprehensive financial audit document, not an annual report (10-K) or a simple announcement. FY 2025
2026-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by HLB Genex. It contains detailed financial tables including consolidated and separate financial statements, audit opinions, and key financial metrics (assets, liabilities, revenue, profit/loss). While it is an announcement of the audit report, it provides the core financial data and audit results required for the annual reporting cycle, which is standard for 10-K filings in the Korean regulatory context (DART). FY 2025
2026-03-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in Korea. This type of filing is a standard regulatory requirement for insiders (directors, executives, and major shareholders) to disclose their holdings and changes in ownership of company securities. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider trades and changes in share ownership by company insiders.
2026-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.